Owlin adds Consumer Sentiment & Review Data to its offering in its journey to transform risk management for Payment Service Providers
12.9.2023 16:00:00 EEST | Business Wire | Press release
Owlin, a global leader in merchant and third-party risk solutions, proudly announces its next big step in advancing the fintech industry: a new Consumer Review Data feature, specifically designed for Risk teams within Payment Service Providers (PSPs). Operational excellence becomes more important than ever for PSPs and manual review processes are often costly, reactive and inefficient. Owlin's latest offering heralds a transformative shift towards proactive, cost-effective, and highly efficient risk management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230912980645/en/
Owlin for Consumer Review Monitoring for Payment Service Providers (PSPs) (Photo: Business Wire)
One of the standout features of Owlin's Consumer Review Feature is its unparalleled ability to detect leading risk signals, such as signs of distress (e.g., delivery- or product issues) well ahead of bigger issues like a bankruptcy event. This capability provides PSPs with a significant advantage in proactively mitigating risk, preventing potential financial disasters, and safeguarding their operations and reputation.
Furthermore, Owlin's Consumer Review Feature is a significant advantage in the world of adverse media monitoring, helping improve merchant risk management. It builds upon Owlin's already world-class monitoring solution for PSPs and it gives PSPs the tools they need to stay competitive.
Key Features and Benefits:
- Real-time Feedback and Risk Alerts - Instantly gather consumer feedback and correlate it with advanced risk signals, alerting PSPs to potential risks well in advance.
- Advanced Analytics - Utilize AI-driven insights powered by large language models to gauge sentiment, track trends, and pinpoint areas requiring risk mitigation.
- Enhanced Engagement and Trust Building - Responsively address concerns, showcase negative reviews, risk mitigating actions, and fortify trust in the PSP ecosystem.
- In-depth Risk Profiles - Craft comprehensive risk profiles based on a blend of signals and consumer feedback, ensuring that risk management decisions are data-driven and merchant-centric.
Stefan Peekel, Chief Growth Officer at Owlin, remarks, “By integrating consumer review data into risk management practices, we're giving PSPs a comprehensive tool that's been absent in the industry. It's not just about enhancing services but also about fortifying them against threats. In essence we now equip PSPs with a magnifying glass and a map. While they get a detailed view of consumer sentiment on a merchant, they also see how signals interconnect, allowing them to preempt risks and capitalize on opportunities.’’
Dedicated to innovation, Owlin keeps pushing to redefine what is possible in the domain of risk management. With this latest consumer review offering Payment Service Providers are equipped with a new set of state of the art tools to manage risk effectively and build trust for merchants and consumers.
About Owlin
Owlin is an AI-driven Third Party Risk and Merchant Monitoring solution that helps businesses feed better and faster risk insights into daily risk management workflows in real time. Owlin applies AI and Natural Language Processing to provide valuable insights hidden in the data and ensures its users don’t get lost in the wealth of information by visualizing complex data in a simple and customizable interface.
For more information, visit https://owlin.com/solutions/consumer-review-monitoring/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230912980645/en/
Contact information
Contact Owlin: Stefan Peekel, stefan@owlin.com, +1 201 932 4580
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
